Rational Design of Novel EGFR Kinase Inhibitors as Anticancer Agents

CNU IR > Pharmacy and Science > 2011 Taiwanese-Russian Organic, Medicinal and Bio Chemistry Interactions & PST Medicinal Chemistry Symposium > Item 310902800/24225

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/24225

Title:	Rational Design of Novel EGFR Kinase Inhibitors as Anticancer Agents
Authors:	Chia-Hsien Wu (吳佳憲) Wen-Hsing Lin (林文星) John T.A. Hsu (徐祖安) Chun-Chen Liao (廖俊臣) Yu-Sheng Chao (趙宇生) Hsing-Pang Hsieh (謝興邦)
Date:	2011
Issue Date:	2011-06-23 14:57:16 (UTC+8)
Abstract:	Lung cancer is the first leading cause of death in human carcinoma, with 80- 85% being non-small cell lung cancer (NSCLC). Over-expression of epidermal growth factor receptors (EGFR) is in 40-80% of NSCLC. Gefitinib (Iressa�) and erlotinib (Tarceva�) were approved by FDA as EGFR inhibitors for the treatment of adenocarcinoma (subtype of NSCLC). Gefitinib and erlotinib competitively bind to the ATP binding pocket of EGFR kinase domain and inhibit its activity. These two drugs showed high response rates in Asian NSCLC patients, but patients became resistant to treatment with gefitinib or erlotinib after 6-12 months. Drug resistance occurs as a result of secondary mutation such as T790M mutation. We designed and synthesized novel EGFR- tyrosine kinase inhibitors, which expect to overcome the resistance issues for potential NSCLC therapy. Through hybrid design and knowledge-based design concepts to obtain cmpounds 4, 5, 6 and 7 with 1-9 nM inhibition against wild type EGFR and HCC827 cell-line (EGFR E746-A750 deletion). This series also showed 10-305 nM inhibition against gefitinib-resistant mutant of EGFR (T790M/L858R). More than 200 analogues were synthesized, and the presence of (S)-phenyl-glycinol and Michael acceptor groups are essential for activity in the series of inhibitors.
Relation:	2011年台俄有機、藥物與生物化學交流暨藥物化學研討會，起迄日：2011/04/06~2011/04/05，地點：溪頭台大實驗林
Appears in Collections:	[Pharmacy and Science] 2011 Taiwanese-Russian Organic, Medicinal and Bio Chemistry Interactions & PST Medicinal Chemistry Symposium

Files in This Item:

File	Description	Size	Format
pp-09.pdf		77Kb	Adobe PDF	500	View/Open

Loading...